☆ 4.6 Review

Primary hyperoxaluria type 1: novel therapies at a glance

CLINICAL KIDNEY JOURNAL (2022)

Related references

Note: Only part of the references are listed.

Letter Urology & Nephrology

Is stiripentol truly effective for treating primary hyperoxaluria?

Cristina Martin-Higueras et al.

CLINICAL KIDNEY JOURNAL (2021)

Add to Collection

Article Transplantation

Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study

Bernd Hoppe et al.

Summary: In PH1 ESRD patients, long-term administration of OC5 was found to significantly reduce Pox concentrations, improve or stabilize cardiac function and clinical status, without increasing dialysis frequency. OC5 was safe and well-tolerated, showing promising results for potential clinical impact.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

Add to Collection

Article Pharmacology & Pharmacy

Lumasiran: First Approval

Lesley J. Scott et al.

Summary: Lumasiran is a drug developed for the treatment of primary hyperoxaluria type 1 by targeting a specific gene to inhibit the synthesis of toxic metabolites. It received approvals in the EU and USA, marking its global recognition.

DRUGS (2021)

Add to Collection

Review Health Care Sciences & Services

Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias

Maria Dolores Moya-Garzon et al.

Summary: Primary hyperoxalurias (PHs) are a group of inherited disorders affecting hepatic glyoxylate metabolism, leading to harmful calcium oxalate crystal accumulation. Developments in small molecule enzyme inhibitors targeting key enzymes show promise for more effective and safe therapeutic options in treating PHs.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Article Urology & Nephrology

Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria

Gema Ariceta et al.

Summary: Inhibition of LDHA by RNAi is a safe and liver-specific therapeutic mechanism for treating all types of PH, as shown by nonclinical and clinical data.

KIDNEY INTERNATIONAL REPORTS (2021)

Add to Collection

Article Urology & Nephrology

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1 A Placebo-Controlled Randomized Clinical Trial

Yaacov Frishberg et al.

Summary: This study evaluated the safety and pharmacodynamic characteristics of Lumasiran in patients with primary hyperoxaluria type 1, showing that Lumasiran has an acceptable safety profile and can reduce urinary oxalate excretion in patients to near-normal levels.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Sander F. Garrelfs et al.

Summary: Primary hyperoxaluria type 1 is a rare genetic disease caused by hepatic overproduction of oxalate, leading to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. This trial tested the efficacy of lumasiran, an RNAi therapeutic agent, in reducing hepatic oxalate production. The results showed that lumasiran significantly reduced urinary oxalate excretion, alleviating the cause of kidney failure in PH1 patients.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Frederick J. Raal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Pediatrics

Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient

Caroline Kempf et al.

PEDIATRIC NEPHROLOGY (2020)

Add to Collection

Article Urology & Nephrology

ALLN-177, oral enzyme therapy for hyperoxaluria

James E. Lingeman et al.

INTERNATIONAL UROLOGY AND NEPHROLOGY (2019)

Add to Collection

Article Medicine, Research & Experimental

Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning

Marine Le Dudal et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology

Julie Esteve et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)

Add to Collection

Review Urology & Nephrology

Molecular basis of primary hyperoxaluria: clues to innovative treatments

Mirco Dindo et al.

UROLITHIASIS (2019)

Add to Collection

Article Urology & Nephrology

A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria

Dawn Milliner et al.

UROLITHIASIS (2018)

Add to Collection

Article Medicine, General & Internal

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

D. Adams et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Pediatrics

A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria

Bernd Hoppe et al.

PEDIATRIC NEPHROLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Kausik K. Ray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Urology & Nephrology

Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure

Fang Zhao et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)

Add to Collection

Review Medicine, General & Internal

Primary Hyperoxaluria

Pierre Cochat et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Urology & Nephrology

Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome

Jerome Harambat et al.

KIDNEY INTERNATIONAL (2010)

Add to Collection

Article Urology & Nephrology

Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1

Sonia Fargue et al.

KIDNEY INTERNATIONAL (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.